Pfizer, BioNTech start study on third COVID-19 booster shot
Pfizer and BioNTech announced they have started a trial to determine the safety and efficacy of a third dose of its COVID-19 vaccine.
MADISON, Wis. — Pfizer and BioNTech announced they have started a trial to determine the safety and efficacy of a third dose of its COVID-19 vaccine Thursday morning.
In a statement, the companies said they will also look at how well it protects against existing and potential variants. The companies said its existing two-dose vaccination process still protects against the variants already circulating.
“While we have not seen any evidence that the circulating variants result in a loss of protection provided by our vaccine, we are taking multiple steps to act decisively and be ready in case a strain becomes resistant to the protection afforded by the vaccine,” Pfizer CEO Albert Bourla said.
Pfizer had announced it was looking at a potential third-dose booster shot earlier this week. The companies said they are in ongoing discussions with the FDA and the European Medicines Agency for its studies.
COPYRIGHT 2021 BY CHANNEL 3000. ALL RIGHTS RESERVED. THIS MATERIAL MAY NOT BE PUBLISHED, BROADCAST, REWRITTEN OR REDISTRIBUTED.